Metastatic Breast Cancer
Conditions
Brief summary
A cross-sectional, non-interventional, observational study using qualitative patient interviews to explore patient experiences and attitudes toward taking capivasertib + fulvestrant as directed
Interventions
OTHERnon-interventional
This is a non-interventional, observational study
Sponsors
AstraZeneca
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
(self-reported): * Adult (over the age of 18 years) * Diagnosed with HR+/HER2- metastatic breast cancer * Received at least 1 week of capivasertib + fulvestrant (Patients will be invited to provide documents demonstrating the use of capivasertib. Patients will be able to participate even if unable to obtain such documentation)
Exclusion criteria
(self-reported): * Patients who had discontinued capivasertib for more than 6 months before the date of the interview * Unable or unwilling to follow study procedures (including providing informed consent) * Not proficient in spoken English, as assessed by the moderator * Receiving capivasertib in a clinical trial setting * Patients who are not able to recall instruction for administration of capivasertib in a manner consistent with the labeling (e.g. 4 days on followed by 3 days off)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Patient attitude and experience reported by patients regarding capivasertib dosing schedule and regimen | Day 1 | The interview will be conducted using a discussion guide tailored to specific questions to be explored in this study, developed by the study team. No formal scale or validated questionnaire will be used to assess the outcomes |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Self-reported tolerability experiences related to patients' ability to follow the prescribed regimen and stay on treatment among those who received capivasertib + fulvestrant. | Day 1 | The interview will be conducted using a discussion guide tailored to specific questions to be explored in this study, developed by the study team. No formal scale or validated questionnaire will be used to assess the outcomes |
Countries
United States
Outcome results
None listed